Jolly Mazumdar, Ph.D., M.B.A.
Co-founder and Chief Executive Officer
Jolly Mazumdar is the Chief Executive Officer of Chimeron Bio. Previously, she served in clinical development leadership roles at GlaxoSmithKline pharmaceuticals in the divisions of Immuno-Oncology and Personalized Oncology where she oversaw the biomarker strategy for two melanoma drugs, Tafinlar and Mekinist. Jolly obtained her Ph.D. in Cell Biology with emphasis in infectious diseases from the University of Georgia. She pursued her postdoctoral training in a Howard Hughes Medical Institute laboratory at the University of Pennsylvania where she explored the role of hypoxia in tumor and stem cell biology. Her research is published in journals including Nature Cell Biology and PNAS. Jolly has an M.B.A. from Columbia Business School.
Tim Chendrimada, Ph.D., M.B.A.
Co-founder and Chief Scientific Officer
Thimmaiah (Tim) Chendrimada brings in 12 years of drug discovery and development experience across therapy areas including cardiovascular and oncology obtained at GlaxoSmithKline (GSK) pharmaceuticals. He has led multiple pre-clinical programs and has expertise working with therapeutic entities including small molecules, antibodies, adeno associated viruses and RNA oligos. Previously, at the Wistar Institute in Philadelphia, he worked on understanding RNA biochemistry, with emphasis on biogenesis and maturation of small RNAs. His research is published in high-profile journals including Nature, Cell, EMBO. Tim obtained his Ph.D. at the University of Georgia and has an MBA from Columbia Business School.